Skip to main content

Table 1 Relation between survivin immunoreactivity and clinicopathological variables of the studied cases

From: Assessment of survivin and p27 expression as potential prognostic markers in urothelial cell carcinoma of urinary bladder in Egyptian patients

Item (n) Survivin immunopositivity p-value Survivin
expression score
p-value
Positive
n (%)
Negative
n (%)
  Low score
n (%)
High score
n (%)
Mild chronic cystitis (12) 0 12 (100)  < 0.001 0 0  < 0.001
Urothelial carcinoma (60) 36 (60) 24 (40) 13 (36) 23 (64)
Age  < 60 years (21) 12 (57) 9 (43) 0.476 9 (75) 3 (25)  < 0.001
 ≥ 60 years (39) 24 (61.5) 15 (38.5) 4 (16.7) 20 (83.3)
Sex Male (54) 35 (64.8) 19 (35.2) 0.033 12 (34.3) 23 (65.7) 0.361
Female (6) 1 (16.7) 5 (83.3) 1 (100) 0
Pattern Papillary (33) 11 (33.3) 22 (66.7)  < 0.001 8 (72.7) 3 (27.3) 0.004
Solid (27) 25 (92.6) 2 (7.4) 5 (20) 20 (80)
Grade Low (23) 5 (21.7) 18 (78.3)  < 0.001 3 (60) 2 (40) 0.239
High (37) 31 (83.8) 6 (16.2) 10 (32.3) 21 (67.7)
Stage Superficial (30) 12 (40) 18 (60) 0.002 8 (66.7) 4 (33.3) 0.01
Deep (30) 24 (80) 6 (20) 5 (20.8) 19 (79.2)
  1. NMIBC Non-muscle invasive bladder cancer, MIBC Muscle-invasive bladder cancer, n Number, % Percentage